New Trial Alert: Alliance A091903 Resected Mucosal Melanoma

June 7, 2022

Alliance A091903: A randomized phase II trial of adjuvant nivolumab with or without cabozantinib in patients with resected mucosal melanoma

Overview: Alliance investigator Alexander Shoushtari, MD, of Memorial Sloan Kettering Cancer Center, leads this phase II trial to test whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, suc

Alliance NCTN/NCORP/AFT at 2022 ASCO

May 18, 2022


The 58th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene in-person June 3-7 in Chicago, bringing together thousands of oncology professionals from around the world. This year's meeting theme is "Advancing Equitable Cancer Care Through Innovation." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be h

Holiday Closure: Memorial Day

May 18, 2022

In observance of the Memorial Day Holiday, Alliance/AFT/Alliance Foundation offices in Boston, Chicago, and at Duke, along with Alliance Statistics and Data Management Center offices in Rochester, will be closed on Monday, May 30. McKesson's Clinical Research Services and most Alliance Biorepositories will also be closed on Monday, May 30. For more details, view the BioMS Holiday Schedule or contact the Clinical Research Service

Older News